Boehringer Ingelheim Press Releases

Boehringer Ingelheim receives approval from the European Commission for Mirapexin®/Sifrol® prolonged-release, once daily tablet for the treatment of Parkinson`s disease

Access to HIV medication

Boehringer Ingelheim`s diabetes pipeline continues to advance as the Company announces conclusion of robust Phase III pivotal trials programme for linagliptin

Boehringer Ingelheim Animal Health enters into agreement to acquire certain assets of Fort Dodge Animal Health from Pfizer

New analysis supports tiotropium as initial maintenance therapy for COPD

Early administration of Aggrenox® is effective and safe after acute ischaemic stroke or TIA

ERS COPD Research Award 2009 sponsored by Boehringer Ingelheim

New data show patients with chronic low back pain maintained pain reduction on duloxetine

Groundbreaking results in the RE-LY® trial - novel oral direct thrombin inhibitor dabigatran etexilate convincingly beats warfarin - superior stroke reduction with less bleeding!

Boehringer Ingelheim to commence Phase III study investigating the role of BIBW 2992 as first-line treatment for non-small cell lung cancer (NSCLC) patients with EGFR mutations

Good first six months in 2009 for Boehringer Ingelheim - Successful products Spiriva®, Micardis® and Flomax® secure good growth

Head-to-head trial demonstrates Viramune®’s similar efficacy and more favourable effect on lipid profile compared to atazanavir/ritonavir

Successful promissory note (Schuldschein) placement

European Commission approves statement on lipid improvement for Viramune® label

Boehringer Ingelheim receives positive recommendation from European scientific committee for a new once daily Mirapexin (pramipexole) formulation for the treatment of Parkinson`s disease

Expedition to Mount Everest offers new insights into chronic disease

Boehringer Ingelheim and Vitae Pharmaceuticals announce a major collaboration to research and develop novel treatments for Alzheimer`s disease

New investigational combination telmisartan and amlodipine shows effective and well-tolerated 24-hour blood pressure control in hypertensive patients at risk of cardiovascular events